Larimar Therapeutics, Inc.
NASDAQ:LRMRBiotechnology
Healthcare
$3.23 +0.99%
+$0.04 today
- Market cap
- $337.45M
- Beta
- 0.82
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$1.95
52W Low $2.22High $6.42
Volume 1.41M
Average 1.73M
Balance Sheet
Inspect the capital base behind the business.
Assets
$145.84M
FY 2025 · Annual
-27.2% YoYLiabilities
$67.76M
FY 2025 · Annual
+138.5% YoYEquity
$78.08M
FY 2025 · Annual
-54.6% YoYBalance Sheet
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 70.1M | 26.83M | 26.75M | 33.22M | 85.41M |
| Short-term Investments | 0 | 91.6M | 60.04M | 150.24M | 51.44M |
| Net Receivables | 208K | 0 | 0 | 1.05M | 747K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 279K | 238K | 709K | 517K | 253K |
| Total Current Assets | 72.2M | 120.74M | 90.18M | 195.3M | 142.02M |
| Property, Plant & Equipment (Net) | 4.46M | 3.69M | 3.76M | 3.72M | 2.69M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 1.34M | 0 | 1.34M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 669K | 1.98M | 659K | 1.2M | 1.13M |
| Total Non-current Assets | 6.46M | 5.67M | 5.76M | 4.92M | 3.82M |
| Total Assets | 78.67M | 126.41M | 95.94M | 200.23M | 145.84M |
| Account Payables | 1.66M | 1.69M | 1.28M | 2.42M | 5.22M |
| Short-term Debt | 0 | 0 | 0 | 0 | 1.11M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 0 | 0 | 54.69M |
| Total Current Liabilities | 8.85M | 10.71M | 9.51M | 24.36M | 64.8M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 5.41M | 4.8M | 4.71M | 4.06M | 2.96M |
| Total Liabilities | 14.25M | 15.5M | 14.22M | 28.41M | 67.76M |
| Common Stock | 18K | 43K | 43K | 64K | 83K |
| Retained Earnings | (116.25M) | (151.61M) | (188.55M) | (269.16M) | (434.83M) |
| Accumulated OCI | (0) | (31K) | 81K | 148K | 54K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 64.41M | 110.9M | 81.72M | 171.81M | 78.09M |
| Total Debt | 6M | 5.41M | 5.55M | 5.12M | 4.07M |
| Net Debt | (64.1M) | (21.42M) | (21.2M) | (28.1M) | (81.35M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $177.9M |
| Short-term Investments | $22.5M |
| Receivables | $791.0K |
| Other Current | $3.8M |
| Total Current Assets | $205.0M |
| PP&E (Net) | $2.4M |
| Other Non-current | $1.1M |
| Total Non-current Assets | $3.5M |
| Total Assets | $208.5M |
Analysis
Selected assets total $208.5M for Latest. The largest visible component is Cash & Equivalents at $177.9M, about 85.3% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 12, 2026 |
How much cash does LRMR have?
Larimar Therapeutics, Inc. (LRMR) reported $85.41M in cash and equivalents in fiscal 2025.
How much debt does LRMR carry?
Larimar Therapeutics, Inc. (LRMR) reported $4.07M of total debt, with net debt of -$81.34M.
Continue the stock analysis
Jump to another research area for this company.